Yamada, Zento
Muraoka, Sei
Kawazoe, Mai
Hirose, Wataru
Kono, Hajime
Yasuda, Shinsuke
Sugihara, Takahiko
Nanki, Toshihiro
Funding for this research was provided by:
Bristol-Myers Squibb K.K. and Ono Pharmaceutical Co., Ltd.
Article History
Received: 2 December 2023
Accepted: 14 April 2024
First Online: 17 April 2024
Declarations
:
: The Ethics committee of Faculty of Medicine, Toho University (Approval number: A20114_A17112_A16017_27038), Teikyo University (14–061) and ethics committees of collaborative institutions approved the study protocol. All participants consented to the study upon enrollment.
: Not applicable.
: SM received speaker’s bureau fees from Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahikasei Pharma Corp., and Astellas Pharma Inc. MK received speaker fees from Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., AstraZeneca K.K., GlaxoSmithKline plc., Nippon Boehringer Ingelheim Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Gilead Sciences Inc. WH received speaker fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., AbbVie GK, Mitsubishi Tanabe Pharma Corp., Nippon Boehringer Ingelheim Co., Ltd., and Bristol-Myers Squibb Co. HK received grant/research support from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahikasei Pharma Corp., and Teijin Pharma Ltd., and speakers fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Medical Co., Ltd., AbbVie GK, Amgen Inc., Celgene Corp., Gilead Sciences Inc., Mitsubishi Tanabe Pharma Corp., UCB Japan Co. Ltd., Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd. and Teijin Pharma Ltd. SY received grants support from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahikasei Pharma Corp., Ayumi Pharmaceutical Corp., AbbVie GK and Taisho Pharmaceutical Co., Ltd., consultant fees from Eisai Co., Ltd., Asahikasei Pharma Corp., Chugai Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., and personal fees from AbbVie GK, Chugai Pharmaceutical Co., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Eli Lilly K.K., GlaxoSmithKline plc., and AstraZeneca K.K. TS received research grants from Asahikasei Pharma Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Ono Pharmaceutical Co., Ltd., and honoraria from AbbVie GK, Asahikasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd. and UCB Japan Co. Ltd. TN received grant/research support from Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Ayumi Pharmaceutical Corp, Nippon Kayaku Co., Ltd., AbbVie GK, Sanofi K.K., Teijin Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Taisho Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd. and Shionogi & Co., Ltd., consultant fees from UCB Japan Co., Ltd., Eisai Co., Ltd. and Chugai Pharmaceutical Co., Ltd., and speakers fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Mylan N.V., AbbVie GK, Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., Kyowa Kirin Co., Ltd., UCB Japan Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., GlaxoSmithKline plc. and Taisho Pharmaceutical Co., Ltd. The remaining author declare that they have no conflicts of interest.